Adverse drug reactions to second line anti tuberculosis drugs: A prospective study in Mumbai, India

S. Natarajan, P. Subramanian (Mumbai, Thane, India)

Source: Annual Congress 2013 –Drug-resistant tuberculosis
Session: Drug-resistant tuberculosis
Session type: Thematic Poster Session
Number: 2820
Disease area: Respiratory infections

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
S. Natarajan, P. Subramanian (Mumbai, Thane, India). Adverse drug reactions to second line anti tuberculosis drugs: A prospective study in Mumbai, India. Eur Respir J 2013; 42: Suppl. 57, 2820

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Spectrum of adverse drug reactions during MDR TB treatment
Source: Annual Congress 2013 –Drug-resistant tuberculosis
Year: 2013

Dynamics analysis of MBT drug resistance to antitubercolosis second-line drugs (Saratov region hospital, Russia)
Source: International Congress 2016 – Update on drug-resistant tuberculosis
Year: 2016

Study on drug sensitivity patterns in tuberculosis in tertiary care in Mumbai
Source: International Congress 2016 – Update on drug-resistant tuberculosis
Year: 2016

Treatment outcome among HIV positive and HIV negative TB patients in Chandigarh, India: A retrospective cohort study
Source: International Congress 2015 – Management of TB: a patient focus
Year: 2015

Effectiveness of mandatory treatment for tuberculosis - An observational registry study
Source: Annual Congress 2013 –Epidemiological and public health features of tuberculosis
Year: 2013

Study of prevalence of drug resistance in tuberculosis (TB) patients attending a tertiary care hospital at Mumbai
Source: International Congress 2016 – Epidemiological insights into tuberculosis pathogenesis
Year: 2016


Preventing MDRTB in Europe: Drug sensitivities received after the initial phase of treatment
Source: International Congress 2016 – Drug-resistant tuberculosis and experiences with delamanid and bedaquiline
Year: 2016


Clofazimine for the treatment of multidrug-resistant tuberculosis: Prospective, multicenter, randomized controlled study in China
Source: International Congress 2015 – TB treatment: new drugs and drug resistance
Year: 2015

Pattern of second line drug-resistance in MDR-TB treatment failure cases at a tertiary care tuberculosis treatment centre in western region of India
Source: International Congress 2016 – Update on drug-resistant tuberculosis
Year: 2016


Prospective study analysing prevalence of XDR TB in Mumbai, India
Source: International Congress 2016 – Epidemiological insights into tuberculosis pathogenesis
Year: 2016


Evaluation of optimal regimens for treatment of rifampicin resistant-tuberculosis: Multicenter, randomized controlled study in China
Source: International Congress 2015 – TB treatment: new drugs and drug resistance
Year: 2015

Active drug-safety monitoring and management for tuberculosis patients treated with bedaquiline and linezolid, Belarus – 2014-2016
Source: International Congress 2016 – Update on drug-resistant tuberculosis
Year: 2016

Current status of fluoroquinolone use for treatment of tuberculosis in Korea
Source: Annual Congress 2013 –Drug-resistant tuberculosis
Year: 2013

MDR TB treatment results of GFATM program implementation in Tomsk, Russia
Source: International Congress 2015 – Management of TB: a patient focus
Year: 2015


Rifampicin (Rif)-resistant tuberculosis (TB) on GeneXpert in Mumbai, India: How effective is the best derived empiric regimen?
Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments
Year: 2016


Estimating costs for treating patients with multi-drug resistant tuberculosis (MDR TB) under the regional tuberculosis control program, Tomsk (Russia)
Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes
Year: 2015

Active pharmacovigilance for multidrug-resistant tuberculosis patients treated with Linezolid, Belarus – 2014-2015
Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes
Year: 2015


Availability of PCR for second-line drugs in Europe
Source: International Congress 2016 – Advances in tuberculosis diagnosis and monitoring of treatment
Year: 2016



In vitro susceptibility of TB- and MDR-TB-strains against linezolid at a local center in Berlin/Germany
Source: Annual Congress 2013 –Diagnostic features of tuberculosis I
Year: 2013

Treatment outcomes among multidrug-resistant tuberculosis (MDR-TB) cases at a referral hospital of infectious diseases in Italy
Source: International Congress 2016 – Update on drug-resistant tuberculosis
Year: 2016